Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine

Transplant Proc. 2001 Feb-Mar;33(1-2):1009-10. doi: 10.1016/s0041-1345(00)02307-1.
No abstract available

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use*
  • Azathioprine / therapeutic use*
  • Basiliximab
  • Cyclosporine / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Graft Rejection
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Infections / etiology
  • Kidney Transplantation / immunology*
  • Male
  • Middle Aged
  • Postoperative Complications / etiology
  • Prednisone / therapeutic use
  • Recombinant Fusion Proteins*

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Cyclosporine
  • Basiliximab
  • Azathioprine
  • Prednisone